Indeed, mutations affecting TGF-β/Nodal/activin signaling has been observed in a wide range of cancers, and better understanding of how TGF-β/Nodal/activin signaling affects intestinal growth might provide a starting point for the development of therapeutic strategies targeting colorectal cancers. This evidence concerns the gene NODAL and colorectal cancer.